Cargando…

Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer

The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been presented to be a prognostic indicator in several types of cancer. However, these issues have not been concluded yet. The present study was therefore performed to determine the prognostic value of NLR and PLR i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Lu, Jing-Jing, Du, Yi-Ping, Feng, Chun-Xia, Wang, Li-Qiang, Chen, Min-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895303/
https://www.ncbi.nlm.nih.gov/pubmed/29561419
http://dx.doi.org/10.1097/MD.0000000000010144
_version_ 1783313630894227456
author Zhang, Yan
Lu, Jing-Jing
Du, Yi-Ping
Feng, Chun-Xia
Wang, Li-Qiang
Chen, Min-Bin
author_facet Zhang, Yan
Lu, Jing-Jing
Du, Yi-Ping
Feng, Chun-Xia
Wang, Li-Qiang
Chen, Min-Bin
author_sort Zhang, Yan
collection PubMed
description The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been presented to be a prognostic indicator in several types of cancer. However, these issues have not been concluded yet. The present study was therefore performed to determine the prognostic value of NLR and PLR in gastric cancer (GC). A total of 182 GC patients, diagnosed between January 2011 and January 2014, were enrolled in the study. The clinicopathological parameters, laboratory analyses, and outcomes were collected. The association between NLR, PLR, and clinicopathological characters was analyzed with univariate and multivariate analyses. NLR was significantly related to age (P = .026), surgery (P = .006), node status (P = .004), and clinical stage (P = .009). The median overall survival (OS) and progression-free survival (PFS) were poor in the High-NLR group (OS: 36.0 vs 20.5 months, P < .001, PFS: 33.0 vs 12.0 months, P < .001) and High-PLR group (OS: 31.5 vs 18.5 months, P = .003, PFS: 26.0 vs 11.0 months, P = .01). Multivariate analyses indicated both surgery [for OS hazard ratio (HR) = 2.092, 95% confidence interval (95% CI): 1.345–3.253, P = .001; for PFS HR = 1.939, 95% CI: 1.259–2.988, P = .003] and NLR (for OS HR = 1.585, 95% CI: 1.011–2.485, P = .045) were independent prognostic factors. Elevated NLR and PLR were related with poor prognosis in GC patients before treatment. The NLR was an independent prognostic factor for OS. More studies should be conducted to address the potential prognostic value of NLR and PLR in GC.
format Online
Article
Text
id pubmed-5895303
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-58953032018-04-18 Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer Zhang, Yan Lu, Jing-Jing Du, Yi-Ping Feng, Chun-Xia Wang, Li-Qiang Chen, Min-Bin Medicine (Baltimore) 5700 The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been presented to be a prognostic indicator in several types of cancer. However, these issues have not been concluded yet. The present study was therefore performed to determine the prognostic value of NLR and PLR in gastric cancer (GC). A total of 182 GC patients, diagnosed between January 2011 and January 2014, were enrolled in the study. The clinicopathological parameters, laboratory analyses, and outcomes were collected. The association between NLR, PLR, and clinicopathological characters was analyzed with univariate and multivariate analyses. NLR was significantly related to age (P = .026), surgery (P = .006), node status (P = .004), and clinical stage (P = .009). The median overall survival (OS) and progression-free survival (PFS) were poor in the High-NLR group (OS: 36.0 vs 20.5 months, P < .001, PFS: 33.0 vs 12.0 months, P < .001) and High-PLR group (OS: 31.5 vs 18.5 months, P = .003, PFS: 26.0 vs 11.0 months, P = .01). Multivariate analyses indicated both surgery [for OS hazard ratio (HR) = 2.092, 95% confidence interval (95% CI): 1.345–3.253, P = .001; for PFS HR = 1.939, 95% CI: 1.259–2.988, P = .003] and NLR (for OS HR = 1.585, 95% CI: 1.011–2.485, P = .045) were independent prognostic factors. Elevated NLR and PLR were related with poor prognosis in GC patients before treatment. The NLR was an independent prognostic factor for OS. More studies should be conducted to address the potential prognostic value of NLR and PLR in GC. Wolters Kluwer Health 2018-03-23 /pmc/articles/PMC5895303/ /pubmed/29561419 http://dx.doi.org/10.1097/MD.0000000000010144 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Zhang, Yan
Lu, Jing-Jing
Du, Yi-Ping
Feng, Chun-Xia
Wang, Li-Qiang
Chen, Min-Bin
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title_full Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title_fullStr Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title_full_unstemmed Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title_short Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
title_sort prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895303/
https://www.ncbi.nlm.nih.gov/pubmed/29561419
http://dx.doi.org/10.1097/MD.0000000000010144
work_keys_str_mv AT zhangyan prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer
AT lujingjing prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer
AT duyiping prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer
AT fengchunxia prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer
AT wangliqiang prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer
AT chenminbin prognosticvalueofneutrophiltolymphocyteratioandplatelettolymphocyteratioingastriccancer